Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Topics Diabetes Fierce 50 Special Report Awards Gala Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Stories Sponsored HLAh iPSC Lines Help Address Cell Therapy Immunogenicity Fronts Teaser iPSC lines are well suited for use as starting material for allogeneic cell therapies through immunogenicity reducing strategies. Sponsored by Catalent Cell & Gene Therapy Sponsored Quality Considerations for a Growing Gene Therapy Field Fronts Teaser Shorter timelines for clinical trials means being ready earlier for the quality requirements of late-stage trials and regulatory reviews. Sponsored by Catalent Cell & Gene Therapy Sponsored Balancing Quality Grade Plasmids and Expedited Timelines for Advanced Therapies Fronts Teaser The key to success in developing and bringing mRNA-, DNA-, viral vector- and cell-based therapies to the market is having a partner like Catalent Sponsored by Catalent Cell & Gene Therapy Sponsored Why Integrated Partners are Critical to Cell and Gene Therapy Success Fronts Teaser Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, and more. Sponsored by Catalent Cell & Gene Therapy Sponsored Avoiding Gene Therapy CMC and Clinical Supply Issues Fronts Teaser Gene therapy manufacturing and clinical supply strategies should be in place early to avoid potential late-stage development delays. Sponsored by Catalent Cell & Gene Therapy Sponsored The Benefit of an Experienced Manufacturing Partner: Leveraging Scale-up and Technology Expertise for Allogeneic Cell Therapy Manufacturing Fronts Teaser Increased demands, cell manufacturing complexity, and tight timelines: Time for the right allogeneic manufacturing partner. Sponsored by Catalent Cell & Gene Therapy Sponsored Partnering Early for Cell and Gene Therapy Manufacturing Fronts Teaser The importance of establishing a manufacturing strategy and leveraging the expertise of a CDMO early in the cell and gene therapy development timeline Sponsored by Catalent Cell & Gene Therapy
Sponsored HLAh iPSC Lines Help Address Cell Therapy Immunogenicity Fronts Teaser iPSC lines are well suited for use as starting material for allogeneic cell therapies through immunogenicity reducing strategies. Sponsored by Catalent Cell & Gene Therapy
Sponsored Quality Considerations for a Growing Gene Therapy Field Fronts Teaser Shorter timelines for clinical trials means being ready earlier for the quality requirements of late-stage trials and regulatory reviews. Sponsored by Catalent Cell & Gene Therapy
Sponsored Balancing Quality Grade Plasmids and Expedited Timelines for Advanced Therapies Fronts Teaser The key to success in developing and bringing mRNA-, DNA-, viral vector- and cell-based therapies to the market is having a partner like Catalent Sponsored by Catalent Cell & Gene Therapy
Sponsored Why Integrated Partners are Critical to Cell and Gene Therapy Success Fronts Teaser Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, and more. Sponsored by Catalent Cell & Gene Therapy
Sponsored Avoiding Gene Therapy CMC and Clinical Supply Issues Fronts Teaser Gene therapy manufacturing and clinical supply strategies should be in place early to avoid potential late-stage development delays. Sponsored by Catalent Cell & Gene Therapy
Sponsored The Benefit of an Experienced Manufacturing Partner: Leveraging Scale-up and Technology Expertise for Allogeneic Cell Therapy Manufacturing Fronts Teaser Increased demands, cell manufacturing complexity, and tight timelines: Time for the right allogeneic manufacturing partner. Sponsored by Catalent Cell & Gene Therapy
Sponsored Partnering Early for Cell and Gene Therapy Manufacturing Fronts Teaser The importance of establishing a manufacturing strategy and leveraging the expertise of a CDMO early in the cell and gene therapy development timeline Sponsored by Catalent Cell & Gene Therapy